Researchers from the University of London, AstraZeneca and GlaxoSmithKline have developed a set of questions for practicing clinicians to consider when reviewing the results of patient-reported outcome (PROs) measures and effectiveness of medical procedures.
Different models of presenting and interpreting PROs discussed in the paper are based on the type of therapy design, patient withdrawal and the selected study population. Although the worked example is a respiratory questionnaire, the principles derived from this study are also applicable to other symptom-based questionnaires.
From the report: ‘For the practicing clinician, the most important consideration is individualising treatment (and treatment goals). To inform such treatment, clinicians need to critically review PRO data. The hope is that the questions posed here will help to build a framework for this critical review’.
Video summary:
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
